Dear colleagues, I hadn't had time to reply to a colleague who wanted to explore the issue of medical archives and ISF visits, who as if by magic published an article in Pharmakronos on 22 March 2011 entitled "Dompé, Msd and Almirall, archives okay".
Already in the past, Dr. Giannetti of Pharmasoft Consulting Srl, the legal representative of the certifying company at national and European level, had clarified some points relating to this topic with his letter.
So I find myself with a certain astonishment after a few days to note that this topic, in addition to attracting the attention of us ISFs, must in some way also interest the pharmaceutical companies that have decided to give their signal.
What perplexes me and I think will also perplex many other readers is the fact that despite all the evidence, also known by AIFA, the Ministry of Health, Doctors and the Regions, no one lifts a finger to cry scandal. All normal. With great nonchalance, aberrant numbers of visits to doctors are indicated, far higher than those required by Italian, European and regional regulations and no one opens a follow-up investigation or asks for information. Everything is silent, and today is the icing on the cake.
As many as 3 companies in the panorama of the Italian pharmaceutical industry which numbers well over 200 are ok with their files. Well, well and the rest? What is tip?
As always, we are at the usual Italian beatings, we are concerned about throwing the wool over our eyes, we are reassured that the full lawfulness and correctness of the data processing has been verified as provided for by Legislative Decree 196/03, using the information limited to indispensable data for the pursuit of the purposes for which they were collected and everything goes as before and better than before.
But in short, did you take us for complete imbeciles?
Why hasn't any pharmaceutical industry poppy deigned to deny these absurd figures? Simple because thanks to a cumbersome and perhaps even "distracted" system, what is happening is considered normality.
What has become a mere commercial push on the drug is portrayed as a normal way of working, as if doctors needed to be reminded every day of the names of the drugs in an obsessive way, because they are prescribers. It's a strange position. If I were a doctor and read the above I would be at least offended by this commercial vision of pharmaceutical companies, but unfortunately chaos reigns so much by now that few dwell on certain thoughts.
However just to finish, in short, someone at the level
